Geneyx Genomex Ltd.

Geneyx Genomex Ltd. is a Delaware-based genomics company founded in 2018. It specializes in next-generation sequencing (NGS) data analysis and clinical genetic interpretation. With a mission to integrate genomics into healthcare and pharmaceutical research, Geneyx has a global presence, operating in 190 hospitals and labs across 50 countries and analyzing over 520,000 samples.

The company offers advanced technologies, including HiFi long-read sequencing and Sequencing by Binding (SBB™) short-read technology. Its primary product, Geneyx Analysis, is a leading platform for NGS interpretation, providing tools for secondary and tertiary analysis of exome and whole genome sequencing. Geneyx also provides clinical interpretation services, pharmacogenomics insights, and its unique Phenotyper® technology, which enhances diagnostic yields. The platform supports applications in human genetics, oncology, and microbiology, serving a diverse clientele that includes hospitals, life-science companies, and pharmaceutical research organizations. Geneyx has been recognized as one of the World's Best Digital Health Companies for 2024.